October 17, 2005

Terumo acquires distribution rights in Japan to medical contrast media
made by Guerbet of France.

We are proud to announce that Terumo Corporation (Headquartered in Shibuya-ku, Tokyo. President: Akira Takahashi) has signed an exclusive distribution agreement with Guerbet SA (Headquartered in France) to distribute "Magnescope Syringe," an MRI contrast medium, "Hexabrix 320" a contrast medium for vascular and urinary tracts and "Lipiodol Ultra Fluid" a contrast medium for lymph and uterine tubes. Terumo will launch these products on January 1, 2006.

A contrast medium is a medical product that enables doctors to inspect organs and locations that cannot be inspected using X-ray or to distinguish unaffected tissue from affected tissue. Different examinations, such as CT and MRI scans, require different types of media.

Terumo holds the top share in the medical device market for products such as catheters and guide wires used in angiographic examination. Since Terumo currently sells products to circulatory and radiology departments at medical institutions, we can expect to create a synergistic effect by introducing a line of contrast media products. Terumo also distributes medical products such as high-calorie IV solutions and pre-filled syringes to medical institutions. These new distribution rights will complement our range of pharmaceuticals and medical device, and further expand and reinforce our business operations.

Overview of products to be sold:

1. Products included in the agreement: Three contrast media
   1. MRI contrast medium "Magnescope Syringe" (Currently sold by Tanabe Seiyaku Co., Ltd.)
   2. Vascular and urinary tract contrast medium "Hexabrix 320" (Same as above.)
   3. Lymph and uterine tube contrast medium "Lipiodol Ultra Fluid" (Currently sold by Nihon Schering KK.)
2. Sales: About ¥1.6 billion (FY2004)
3. Scope: Exclusive distribution rights in Japan to the 3 products listed above.
4. Planned launch date: January 1, 2006
5. Remarks: There will be no transfer of personnel or facilities to Terumo regarding this transaction.
   

[For your information] About Guerbet SA

1. Company name: Guerbet SA.
2. Scope of business: Manufacture and sale of medical contrast media
3. CEO: Philippe Decazes
4. Head office: France
5. Sales: EUR2.48 million (actual result for 2004)
   

(Note) Forward-looking statements included in this release were determined by Terumo based on the best information available at the time of writing and are subject to potential risks and uncertainties. Therefore, please note that, due to various factors, the actual implementation may differ from what is described here.